期刊文献+

密集化疗与常规化疗对裸鼠人乳腺癌移植瘤抗瘤活性的对比研究 被引量:2

Study on anti-tumor activity between dose-dense chemotherapy and conventional chemotherapy in nude mice with human breast carcinoma
下载PDF
导出
摘要 目的:观察人乳腺癌裸鼠模型剂量密集化疗和常规化疗疗效差异。方法:用乳腺癌MCF-7细胞株建立人乳腺癌裸鼠模型,分组分别进行剂量密集化疗和常规化疗,观察裸鼠模型的一般情况、体质量、外周血白细胞和瘤体积的变化,计算肿瘤的抑瘤率。结果:密集组与常规组瘤体积均比对照组缩小,密集组缩小较常规组更明显,P=0.003。密集组与常规组化疗前后体质量无明显变化。密集组与常规组化疗后外周血白细胞较化疗前明显下降,但两者差异无统计学意义,P=0.940。结论:在乳腺癌裸鼠模型中,剂量密集化疗效果优于常规化疗,且耐受较好。 OBJECTIVE: To observe the difference between dose-dense chemotherapy and conventional chemotherapy separately treating human breast carcinoma model in nude mice. METHODS: The experiment was based on the nude mice model of MCF-7 cell lines, and the general condition, weight, peripheral leukocytes, volume changes of tumor and tumor inhibitory rate were investigated after the conventional and dose-dense chemotherapy. RESULTS: The tumor volume in both dose-dense group and conventional group decreased, and the dose-dense group was more significantly, P = 0. 003. The weight of mice had no significant changes in each group after the treatment, but peripheral leukocytes decreased significantly in both treatment groups, and there was no statistical difference between the two treatment groups, P= 0. 940. CONCLUSIONS: Doseense chemotherapy is better than conventional chemotherapy in breast cancer in this experiment. The nude mice show good tolerance.
出处 《中华肿瘤防治杂志》 CAS 2008年第6期412-414,共3页 Chinese Journal of Cancer Prevention and Treatment
基金 湖南省卫生厅科研资助项目(C2006_036)
关键词 乳腺肿瘤/药物疗法 剂量效应关系 药物 小鼠 breast neoplasms/drug therapy dose-response relationship, drug mice, nude
  • 相关文献

参考文献5

  • 1Citron M L, Berry D A, Cirrineione C. Randomized trial of dosedense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741 /Cancer and Leukemia Group B Trial 9741[J]. J Clin Oncol, 2003, 21(8): 1431-1439.
  • 2Venturini M, del-Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial[J]. J Natl Cancer Inst,2005,97(23): 1724-1733.
  • 3Ballestrero A, Montemurro F, Gonella R, et al. Dose-dense vinorelbine and paelitaxel with granuloeyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity andperipheral blood progenitor cell mobilization eapability[J]. Breast Cancer Res Treat, 2003, 82(3): 185-190.
  • 4Piedbois P,Serin D, Priou F,et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: doeetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epiruhicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase Ⅱ study[J]. Ann Oncol, 2007,18(1) :52-57.
  • 5Norton L. Evolving concepts in the systemic drug therapy of breast cancer[J]. Semin Oncol, 1997, 24(4 Suppl 10) : 3-10.

同被引文献9

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部